Volume 25, Number 1—January 2019
Research
Risk Factors for Elizabethkingia Acquisition and Clinical Characteristics of Patients, South Korea
Min Hyuk Choi, Myungsook Kim, Su Jin Jeong, Jun Yong Choi1
, In-Yong Lee, Tai-Soon Yong, Dongeun Yong, Seok Hoon Jeong, and Kyungwon Lee1
, In-Yong Lee, Tai-Soon Yong, Dongeun Yong, Seok Hoon Jeong, and Kyungwon Lee1
Table 5
Results of univariable and multivariable analyses of risk factors for in-hospital mortality of patients with a true pathogen of Elizabethkingia in a tertiary teaching hospital, Seoul, South Korea
| In-hospital mortality |
Total, n = 30 |
Survived, n = 20 |
Died, n = 10 |
p value |
| Median age, y (range) | 68.5 (61.0–80.0) | 69.5 (60.5–79.5) | 66.5 (63.0–80.0) | 0.86 |
| Male sex, no. (%) | 19 (63.3) | 11 (55.0) | 8 (80.0) | 0.35 |
| Patients from the 3 study wards, no. (%) | 7 (23.3) | 5 (25.0) | 2 (20.0) | 0.99 |
| Nosocomial infection, no. (%) | 29 (96.7) | 19 (95.0) | 10 (100.0) | 0.99 |
| Median Charlson comorbidity index (range) |
6 (5.0–9.0) |
6 (4.5–7.5) |
6 (5.0–9.0) |
0.93 |
| Clinical condition | ||||
| Median hospitalization day of acquisition (range) | 26.5 (13.0–58.0) | 20.5 (12.0–32.0) | 52.5 (26.0–81.0) | 0.03 |
| Median length of hospitalization, d (range) | 47.5 (29.0–89.0) | 38.5 (27.5–67.5) | 77.5 (54.0–210.0) | 0.04 |
| Mechanical ventilation, no. (%) | 24 (80.0) | 15 (75.0) | 9 (90.0) | 0.63 |
| Steroid use, no. (%) |
14 (46.7) |
9 (45.0) |
5 (50.0) |
0.99 |
| Antimicrobial treatment, no. (%) | ||||
| Penicillin* | 5 (16.7) | 3 (15.0) | 2 (20.0) | 0.99 |
| 1st-generation cephalosporin | 3 (10) | 2 (10.0) | 1 (10.0) | 0.99 |
| 2nd-generation cephalosporin | 5 (16.7) | 4 (20.0) | 1 (10.0) | 0.86 |
| 3rd-generation cephalosporin | 8 (26.7) | 4 (20.0) | 4 (40.0) | 0.47 |
| 4th-generation cephalosporin | 7 (23.3) | 4 (20.0) | 3 (30.0) | 0.88 |
| Aminoglycoside | 1 (3.3) | 1 (5.0) | 0 | 0.99 |
| Glycopeptide | 13 (43.3) | 6 (30.0) | 7 (70.0) | 0.09 |
| Linezolid | 4 (13.3) | 2 (10.0) | 2 (20.0) | 0.85 |
| Carbapenem | 7 (23.3) | 2 (10.0) | 5 (50.0) | 0.05 |
| Tetracycline | 8 (26.7) | 7 (35.0) | 1 (10.0) | 0.30 |
| Colistin | 3 (10) | 0 | 3 (30.0) | 0.05 |
| Trimethoprim/sulfamethoxazole | 7 (23.3) | 2 (10.0) | 5 (50.0) | 0.05 |
| Lincosamide | 5 (16.7) | 1 (5.0) | 4 (40.0) | 0.06 |
| Macrolide | 1 (3.3) | 0 | 1 (10.0) | 0.72 |
| Fluoroquinolone | 9 (30) | 4 (20.0) | 5 (50.0) | 0.21 |
| Other | 5 (16.7) | 2 (10.0) | 3 (30.0) | 0.39 |
*Includes aminopenicillin, β-lactam/β-lactamase inhibitor.
1These authors contributed equally to this article.
Page created: December 17, 2018
Page updated: December 17, 2018
Page reviewed: December 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.